We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $47.88 · 8 analysts
Stored first · Google News · Yahoo Finance (English)
How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23% - Zacks Investment Research
How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23% Zacks Investment Research
Why Ascentage Pharma Group Internat (AAPG) Is Gaining Attention in Cancer Drug Development - Yahoo Finance
Why Ascentage Pharma Group Internat (AAPG) Is Gaining Attention in Cancer Drug Development Yahoo Finance
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 03. 25. | After market close (AMC) | $-0.58 | — | — | $132.29M | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 04. 13. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 03. 26. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2025. 12. 05. | Oppenheimer | — | Initiate coverage | — → Outperform | — | Oppenheimer: Outperform |
| 2025. 11. 25. | Truist Securities | — | Initiate coverage | — → Buy | — | Truist Securities: Buy |
| 2025. 11. 10. | BTIG | — | Initiate coverage | — → Buy | — | BTIG: Buy |
| 2025. 11. 05. | Piper Sandler | — | Initiate coverage | — → Overweight | — | Piper Sandler: Overweight |
Price data
No holdings data to show.